A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.

Trial Details

NCT ID
NCT07391657
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • AZD0120
  • Daratumumab
  • Carfilzomib
  • Dexamethasone
  • Bortezomib
  • Pomalidomide
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Tucson, Arizona, United States|32.22174,-110.92648
  • La Jolla, California, United States|32.84727,-117.2742
  • Sacramento, California, United States|38.58157,-121.4944

Key Eligibility Criteria

  • Age ≥ 18 years
  • Documented diagnosis of multiple myeloma according to the IMWG diagnostic criteria
  • Documented evidence of measurable disease:
  • Serum M-protein level ≥ 1 g/dL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →